Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
10.0
5.5
Journals
Pharmaceutics
Special Issues
Small-Molecule Inhibitors for Novel Therapeutics
share announcement

Small-Molecule Inhibitors for Novel Therapeutics

A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Drug Targeting and Design".

Deadline for manuscript submissions: 20 August 2025 | Viewed by 2041

Special Issue Editors

Dr. Gustavo Provensi

E-Mail Website
Guest Editor
Department of Neurosciences, Psychology, Drug Research and Child Health (NEUROFARBA)—Pharmacology and Toxicology Session, University of Florence (UNIFI), 50139 Florence, Italy
Interests: neuropharmacology; neuroscience; drug discovery; brain histamine; brain carbonic anhydrases; oxytocin
Special Issues, Collections and Topics in MDPI journals
Dr. Simone Giovannuzzi

E-Mail Website
Guest Editor
NEUROFARBA Department, Pharmaceutical and Nutraceutical Section, University of Florence, Via U. Schiff 6, Sesto Fiorentino, 50019 Florence, Italy
Interests: medicinal chemistry; protein inhibition/activation; organic synthesis; enzymology
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Small-molecule inhibitors represent a promising frontier in the development of novel therapeutics. These compounds are designed to specifically interact with and inhibit the function of target proteins that play critical roles in disease processes. By binding to these proteins, small-molecule inhibitors can disrupt pathological signaling pathways, offering a strategic approach to treating conditions such as cancer, autoimmune disorders, and infectious diseases. Recent advances in molecular biology and high-throughput screening have enabled the identification of previously undruggable targets, expanding the potential applications of these inhibitors. This Special Issue aims to describe recent developments in the research on small molecules, with a focus on enhancing their specificity, potency, and safety profiles toward novel therapeutic targets; small molecules drug delivery. Original research articles and reviews are welcome.

You may choose our Joint Special Issue in Pharmaceuticals.

Dr. Gustavo Provensi
Dr. Simone Giovannuzzi
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • small molecules
  • enzyme inhibition/activation
  • protein modulation
  • novel therapeutics
  • high-throughput screening
  • target proteins
  • drug delivery

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

32 pages, 7722 KiB  
Article
Rational Design and Synthesis of a Novel Series of Thiosemicarbazone-Containing Quinazoline Derivatives as Potential VEGFR2 Inhibitors
by Alexandru Șandor, Ovidiu Crișan, Gabriel Marc, Ionel Fizeșan, Ioana Ionuț, Cristina Moldovan, Anca Stana, Ilioara Oniga, Adrian Pîrnău, Laurian Vlase, Andreea-Elena Petru, Ionuț-Valentin Creștin, Alex-Robert Jîjie, Brîndușa Tiperciuc and Ovidiu Oniga
Pharmaceutics 2025, 17(2), 260; https://doi.org/10.3390/pharmaceutics17020260 - 15 Feb 2025
Cited by 1 | Viewed by 1471
Abstract
Background/Objectives: Angiogenesis plays a crucial role in tumor development and is a driving force for the aggressiveness of several types of cancer. Our team developed a novel series of thiosemicarbazone-containing quinazoline derivatives, TSC1-TSC10, as potential VEGFR2 inhibitors with proven anti-angiogenic and antiproliferative [...] Read more.
Background/Objectives: Angiogenesis plays a crucial role in tumor development and is a driving force for the aggressiveness of several types of cancer. Our team developed a novel series of thiosemicarbazone-containing quinazoline derivatives, TSC1-TSC10, as potential VEGFR2 inhibitors with proven anti-angiogenic and antiproliferative potential. Methods: The TSC1-TSC10 series was synthesized and characterized by spectral data. Extensive methodology was applied both in vitro (Alamar Blue assay, Scratch assay, CAM assay, and VEGFR2 kinase assay) and in silico (docking studies, MDs, and MM-PBSA) for the confirmation of the biological potential. Results: TSC10 emerged as the most promising compound, with a favorable cytotoxic potential across the cell panel (Ea.Hy296, HaCaT, and A375) in agreement with the in vitro VEGFR2 kinase assay (IC50 = 119 nM). A comparable motility reduction in the vascular endothelial cells to that of the reference drug sorafenib was provided by TSC10, with a similar anti-angiogenic potential in the more complex in ovo model of the CAM assay. The in silico experiments confirmed the successful accommodation of the active site of the kinase domain similar to sorafenib for the entire TSC1-TSC10 series, providing valuable key insight into the complex stability driving force for the evaluated compounds. Conclusions: The in vitro evaluations of the biological potential correlated with the in silico predictions by computer-aided complex simulations provided a solid confirmation of the initial hypothesis for the TSC1-TSC10 series. Full article
(This article belongs to the Special Issue Small-Molecule Inhibitors for Novel Therapeutics)
►▼ Show Figures

Graphical abstract

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop